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ABSTRACT
Metastasis is the leading cause of death in breast cancer
patients. However, the mechanisms underlying metasta-
sis are not well understood and there is no effective treat-
ment in the clinic. Here, we demonstrate that in MMTV-
PyMT, a highly malignant spontaneous breast tumor
model, IL-25 (also called IL-17E) was expressed by tumor-
inﬁltrating CD4+ T cells and macrophages. An IL-25 neu-
tralization antibody, while not affecting primary tumor
growth, substantially reduced lung metastasis. Inhibition
of IL-25 resulted in decreased type 2 T cells and macro-
phages in the primary tumor microenvironments, both
reported to enhance breast tumor invasion and subse-
quent metastasis to the lung. Taken together, our data
suggest IL-25 blockade as a novel treatment formetastatic
breast tumor.
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INTRODUCTION
Breast cancer is themost common, invasive cancer inwomen.
Although early diagnosis and surgical removal of the primary
tumor can effectively reduce the mortality, tumor relapse and
metastasis to lung, liver and bone marrow remain a primary
cause of death in breast cancer patients. Different mouse
models have been developed to study the mechanism
underlying human breast cancer development. For examples,
intravenous injection of tumor cells are useful in studying
tumor dissemination and colonization to the secondary organ,
while syngeneic and xenograft tumor transplantation models
are often used to study the mechanism of tumor invasiveness
at early and later stages. Genetically engineered mouse
models, such as over-expression of oncogenes (i.e. c-myc
(McCormack et al., 1998; D’Cruz et al., 2001), ErbB2 (Guy
et al., 1992; Moody et al., 2002, PyMT (Maglione et al., 2001),
Wnt1 (Tsukamoto et al., 1988), andRAS (Nielsen et al., 1991))
or disruption of tumor suppressor genes (p53 (Lin et al., 2004),
Brca1 (Venkitaraman 2002), or Pten (Di Cristofano and Pan-
dolﬁ 2000) for example), are particularly useful in investigating
the progression of in situ breast tumor development and
spontaneous metastasis.
Earlier studiesbasedonvarious tumormodelshave revealed
an essential role of immune cells in controlling metastasis of
breast tumors. Among them, tumor-associated macrophages
were implicated in all stages in tumor metastasis by modifying
the behavior of cancer cells (Noy and Pollard, 2014; Kitamura
et al., 2015). Deﬁciency in Csf1, the key gene controlling the
development of macrophages, signiﬁcantly reduced tumor
metastasis to the lung in the MMTV-PyMT transgenic mice (Lin
et al., 2001). Further studies indicate that tumor-associated
macrophages promotemetastasis by producing pro-angiogenic
factors such as VEGF and matrix metalloproteinase (Giraudo
et al., 2004; Lin et al., 2006). Moreover, tumor-associated
macrophages can suppress the inﬁltration and anti-tumor
response of CD8+ Tcells and NK cells (Noy and Pollard, 2014).
Tumor-associated macrophages could also directly promote
invasion and extravasation of tumor cells by secreting cytokines
and extracellular matrix-remodeling enzymes.
Several lines of evidences have also demonstrated an
important role of Th2 cells in controlling the progress and
metastasis of tumors (Coussens et al., 2013), particularly
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through secreting interleukin-4 (IL-4), whichmaymodulate the
polarization and effector function of type 2macrophages (M2).
For examples, IL-4 was reported to promote the growth,
angiogenesis, and invasion of tumor cells by inducing
cathepsin activity inmacrophages (Gocheva et al., 2010). Th2
cells, through secreting IL-4, were shown to potentiate pul-
monary metastasis through M2 macrophages to activate
epidermal growth factor receptor (EGFR) signaling in malig-
nant mammary epithelial cells (DeNardo et al., 2009). Inter-
estingly, high levels of Th2 cell-derived cytokines were
reported in the sera of different types of human breast cancer
patients, and the levels of IL-4 and the number of tumor-inﬁl-
trating CD4+ T cells were found to positively correlate with
tumor progression and metastasis to sentinel lymph nodes
(Pedroza-Gonzalez et al., 2011; Kohrt et al., 2005; Mantovani
et al., 2008), highlighting the clinical relevance of type 2
immune cells in the pathogenesis of human breast tumors.
IL-25 (also named as IL-17E), a member of the IL-17 family
cytokines, has been shown to be expressed bymany different
types of cells, including lung and intestinal epithelial cells, Th2
cells, mast cells, eosinophils, basophils, macrophages etc,
with its receptor IL-17RB expressed by ﬁbroblasts, epithelial
cells, Th2 cells, ILC2 cells and macrophages (Licona-Limon
et al., 2013; Fahy 2015). Previous studies by others and us
have demonstrated an important role of IL-25 in regulating the
differentiation and function of Th2 cells and type 2 immune
response in various models (Fort et al., 2001; Angkasekwinai
et al., 2007; Wang et al., 2007; Barlow and McKenzie 2009).
The role of IL-25 in breast cancer has remained largely
unknown. Of particular interests, recent studies suggest that
IL-25 may play an anti-tumor role in several in vitro and
in vivo systems. For examples, IL-25 was shown to directly
act on and induce apoptosis of breast cancer cells (Furuta
et al., 2011). In addition, treatment with IL-25 was reported to
reduce tumor growth in several xenograft tumor models,
including melanoma, breast, lung, colon, and pancreatic
cancers (Benatar et al., 2010). In contrast to these obser-
vations, elevated expression of IL-25 receptor IL-17RB was
shown to have a strong correlation with poor prognosis in
breast cancer patients and a strong pro-tumor activity in
breast tumor models, through regulating NF-κB-mediated
anti-apoptotic pathway (Huang et al., 2014), or inﬂammatory
chemokine expression, including CCL20/CXCL1/IL-8/TFF1
(Wu et al., 2015). In this work, we investigated the role of IL-
25 in a widely used spontaneous breast cancer model, the
MMTV-PyMT transgenic mice with lung as the major
metastasis site (Guy et al., 1992). We found that IL-25 pro-
moted tumor metastasis to the lung, possibly via regulating
type 2 immune responses in the tumor microenvironments.
RESULTS
IL-25 expression in mammary adenocarcinoma
IL-25 has been reported to express in breast tumor speci-
men (Mombelli et al., 2015). For a further understanding of
the clinical relevance of IL-25, we examined IL-25 expres-
sion in all the four major molecular subtypes of human breast
tumors, including Luminal A, Luminal B, Triple negative/
basal-like, and HER2-enriched types, by immunohisto-
chemical analysis. To our surprise, IL-25 expression was
observed in all the 40 clinical sections examined according
to immunohistochemistry staining (Fig. S1A). It is noted that
tumor-associated epithelial cells expressed higher levels of
IL-25 compared with the para-tumor areas as shown by the
positive areas (Fig. 1A). However, we did not found any
difference of IL-25 expression levels among four groups
through counting integrated optic density by Image Pro Plus
(Fig. S1B). Interestingly, tumor-inﬁltrating cells also exhibited
copious IL-25 expression in the tumor, in all the four types of
breast cancers examined.
To further study the role of IL-25 in breast cancer devel-
opment, we utilized a mouse model of spontaneous breast
tumor - the MMTV-PyMT transgenic mouse. In this model,
the polyoma virus middle T antigen is expressed under the
control of mammary gland-speciﬁc promoter MMTV. A major
advantage of this model is that all the transgenic mice will
develop spontaneous multifocal mammary adenocarcino-
mas and lung metastasis within a relative short time period
and tumor progression closely mimics human breast cancer
at four distinct stages, i.e. hyperplasia (4–6 weeks old),
adenoma/mammary intraepithelial neoplasia (8–9 weeks
old), and early carcinoma (8–12 weeks old) and late carci-
noma (over 10 weeks old) (Lin et al., 2003). Tumor
microenvironments at both primary and metastatic sites are
known to play an important role in metastasis (Chambers
et al., 2002), we thus examined the expression of IL-25 in
both the primary tumor and the metastatic lung. Whole
breast tissues from MMTV-PyMT and wild-type (WT) control
mice were extracted and analyzed for IL-25 expression. The
mRNA analysis showed a signiﬁcant increase of IL-25
expression in the tumor tissues compared with normal
mammary tissues (Fig. 1C). Consistent with our ﬁndings in
human breast tissues, the immunohistochemical analysis
also revealed that tumor-inﬁltrating cells in MMTV-PyMT
mice expressed high levels of IL-25 (Fig. 1B). To determine if
IL-25 is expressed at the metastatic site, metastatic lung
sections from tumor-bearing MMTV-PyMT mice were stained
with IL-25 by IHC, but there was no IL-25 expression in both
tumor and paratumor area (Fig. 1B), suggesting that IL-25 is
mainly derived from the primary tumor sites.
Macrophages and T cells are often present at abundant
numbers in various tumors (Mantovani et al., 2008). To
determine whether these cells express IL-25 in the tumor
microenvironment, immunoﬂuorescence staining was per-
formed in which macrophages were stained by anti-F4/80
whereas CD4+ Tcells were stained by anti-CD4. Most F4/80
+ or CD4+ cells were co-stained with anti-IL-25, suggesting
that these cells are the major source of IL-25 in the tumor
(Fig. 1D). For further conﬁrmation, CD4+ T cells and CD11b
+F4/80+Gr-1- macrophages were puriﬁed from tumor tis-
sues, and analyzed for the mRNA expression of IL-25.
RESEARCH ARTICLE Zhujun Jiang et al.









Consistent with the immunoﬂuorescence results, IL-25
expression in tumor-associated CD4+ cells and macro-
phages was >50 folds higher than in CD45- cells (Fig. 1E).
These mRNA and IHC data also suggest that tumor cells are
not a major source of IL-25.
Anti-IL-25 treatment reduced lung metastasis
To address the function of IL-25 in tumor progression and
metastasis, MMTV-PyMT mice were treated with an anti-IL-
25 antibody or control antibody (Rat IgG) at the onset time of
primary tumors (∼4–5 week of age). The rat anti-mouse IL-
25-speciﬁc blocking antibody was previously generated in
our lab (Angkasekwinai et al., 2007), and widely used by the
allergy ﬁeld (Duan et al., 2010; Kaiko et al., 2010; Siegle
et al., 2011; Angkasekwinai et al., 2013; Hong et al., 2014).
The treatment continued for 10 weeks (200 μg, twice per
week). Although the development of primary tumor (Fig. 2A)
and the survival rate (Fig. S2) of MMTV-PyMT mice were not
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Figure 1. Macrophages and CD4 cells expressed IL-25 inside mammary adenocarcinoma. (A) Image Pro Plus characterized
IHC-staining of IL-25 (×10 magniﬁcation) in human breast paratumor and carcinoma, and the IL-25+ cells through counting the
relative positive area. (B) IHC-staining of IL-25 in mouse breast carcinoma and metastatic lung tissues of the MMTV-PyMT transgenic
mice. (C) The relative mRNA level of Il25 in breast tissues isolated from wide type and the MMTV- PyMT mice (14 weeks old) WT:
wide type mice; Tg: MMTV- PyMT transgenic mice. (D) Immunoﬂuorescence staining of IL-25 (red), CD4 (green) or F4/80 (green) in
the mammary carcinomas tissues of the MMTV-PyMT mice, and the merged images were shown at the left side. (E) The relative Il25
mRNA level in the tumor inﬁltrating CD4+ T cells (CD4: CD45+CD11b-CD3+CD4+), macrophages (TM: CD45+CD11b+F4/80+Gr-1-)
and CD45- cells (TC) isolated from the mammary carcinomas of MMTV-PyMT mice (14 weeks old).
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metastasis by >60%, as determined by the numbers of tumor
nodes (Fig. 2B). In addition, the size of metastatic tumors
was also signiﬁcantly reduced as determined by tumor area
inside the lung (Fig. 2C).
CD4+ T cells in the tumor microenvironment expressed
IL-17RB
IL-25 can act on both non-hematopoietic cells, for example
breast epithelial cells, and hematopoietic cells, such as
eosinophils, CD4+ T cells, NKT cells and type 2 innate
lymphocytes etc. To determine the cells responding to IL-25
in the tumor microenvironment, we analyzed the expression
of IL-17RB, the speciﬁc receptor for IL-25, in tumors (CD45-)
and tumor-inﬁltrating immune cells, including CD4+ T cells
(CD45+CD3+CD11b-CD4+), CD8+ T cells (CD45+CD3
+CD11b-CD8+), NK cells (CD45+CD11b-DX5+), γδ T cells
(CD45+CD3+CD11b-γδTCR+) and macrophages (CD45
+CD3-CD11b+F4/80+Gr-1-), by ﬂow cytometry (Fig. 3A).
Interestingly, IL-17RB was selectively expressed by intra-
tumor CD4+ T cells, but not CD8+ T, NK, γδ T cells or
macrophages. For further conﬁrmation, we sorted tumor
macrophages (CD45+CD11b+F4/80+Gr-1-), tumor-inﬁltrat-
ing CD4+ (CD45+CD4+CD11b-), and CD45- cells, and then
examined the mRNA level of IL-17RB in these cells. The
mRNA results were consistent with the staining data that
only CD4+ T cells expressed IL-17RB (Fig. 3B). In addition,
we failed to detect IL-17RB in CD45- cells as determined by
both surface staining and mRNA analysis, indicating that
tumor cells may not respond to IL-25 directly. This is in
contrast to the former report that IL-25 can cause apoptosis
of breast cancer cells in vitro.
Anti-IL-25 dampened Th2 response in the primary
tumor tissue
IL-25 has been shown to promote Th2-associated pathology
by inducing IL-4, IL-5, IL-13 and IL-9 expression (Fort et al.,
2001; Angkasekwinai et al., 2007; Angkasekwinai et al.,
2010). To address the possibility that IL-25 may also affect
Th2 response inside primary breast tumors, we analyzed
tumor-inﬁltrating IL-4-, IL-5- and IL-13-secreting CD4+ Tcells
in primary adenocarcinomas of MMTV-PyMT mice, and
found that IL-25 blocking antibody signiﬁcantly decreased
the numbers of IL-4-secreting CD4+ cells while had no effect
on IL-5 and IL-13 expression (Fig. 4A). We also analyzed
ILC2, eosinophils, Th17, Treg, NK, γδ T cells, macrophages
and MDSCs (MDSCs Myeloid-derived suppressor cells)
(Fig. S3), since these immune cells have been shown to
function in different tumor models. Interestingly, we did not
observed any noticeable changes in the percentages and
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Figure 2. Anti-IL-25 blocking antibody reduced lung metastasis. The MMTV-PyMT mice were treated with either anti-IL-25
antibody or isotype control antibody starting from 4–5 weeks old, and sacriﬁced at 14 weeks old. (A) The size of primary tumors
(mean ± SE). (B) Representative images of lung tissues isolated from the MMTV-PyMT and WT mice. The numbers of tumor nodes
on the surface of lungs were shown as mean ± SE. (C) Representative H&E staining images of the lung tissues isolated from the
MMTV-PyMT mice treated with either Rat IgG or anti-IL-25 antibody (×10 magniﬁcations). The relative tumor areas were shown as
mean ± SE and analyzed by Student’s t test.
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particularly Granzyme B+ CD8+ T cells, which were
increased after anti-IL25 treatment (Fig. 4B).
Anti-IL-25 treatment altered intra-tumor macrophage
polarization
IL-4 can directly regulate the phenotypes and effector func-
tion of tumor-associated CD11b+Gr-1-F4/80+ macrophages,
which were reported to promote the invasive and metastatic
behavior of malignant mammary epithelial cells by secreting
EGF and activating EGFR signaling programs in tumor
epithelial cells (DeNardo et al., 2009). Since anti-IL-25
treatment resulted in a reduction of IL-4-producing Th2 cells,
we then examined the polarization of tumor macrophages in
the MMTV-PyMT tumor model. Interestingly, in the primary
tumor, CD206+ macrophages were signiﬁcantly reduced
after anti-IL-25 antibody treatment (Fig. 5A), which were
reported to promote tumor growth and metastasis (Van
Dyken and Locksley, 2013). Consistently, the tumor tissue
showed reduced expression of Il10, an M2 macrophage-
associated gene, and increased expression of Il12, a marker
gene for the M1 macrophages. In addition, Ym-1, a chiti-
nase-like molecule expressed by alternatively activated tis-
sue macrophages that can inhibit the function of effector
CD8+ T cells, was also signiﬁcantly reduced after anti-IL-25
antibody treatment (Fig. 5B). These results indicate that anti-
IL-25 treatment reduced M2 macrophages in breast cancer.
DISCUSSION
The understanding of cancer-associated inﬂammation in the
tumor microenvironments would facilitate the development of
novel immunotherapeutic approaches against various
tumors by either stimulating anti-tumor or inhibiting pro-tumor
inﬂammatory responses (Balkwill and Mantovani, 2012).
Previous studies have established an important role of type 2
immune cells in promoting tumor progression and metasta-
sis in breast cancer. Through targeting IL-25, an IL-17 family
cytokine that positively regulates the initiation of type 2
immune response, we found that anti-IL-25 blocking anti-
body treatment led to more than 50% reduction of pulmonary
metastasis in a spontaneous breast tumor model—the
MMTV-PyMT transgenic mice, accompanied with reduced
Th2 and M2 cells in the primary tumor tissue.
IL-25 was abundantly expressed in the primary sites of
both human and mouse breast tumors, but not in the meta-
static lung in the MMTV-PyMT tumor model. We found that
only tumor-inﬁltrating CD4+ T cells, but not CD8+ T, macro-
phages or tumor cells express IL-17RB – the receptor for IL-
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Figure 3. Expression of IL-17RB. The expression of IL-17RB was analyzed in mammary tumor-inﬁltrating cells isolated form the
MMTV-PyMT primary tumor by ﬂow cytometry (red) compared with isotype control (black) (A), or in sorted tumor inﬁltrating CD4 +
(CD4:CD45+CD11b-CD3+CD4+) cells, macrophages (TM: CD45+CD11b+ F4/80+Gr-1-) and CD45- cells (TC) by relative mRNA
expression (B).
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25 blocking antibody signiﬁcantly reduced IL-4-producing
CD4+ Th2 cells in the MMTV-PyMT breast tumor model
(Fig. 4A). Previous studies showed that IL-4 could enhance
the invasive behavior of malignant MECs (mammary
epithelial cells) and promote their dissemination and out-
growth in the lung through regulating the polarization of M2
macrophages. (DeNardo et al., 2009). Consistently, anti-IL-
25 blocking antibody treatment also caused a decrease of
M2 macrophages in the tumor microenvironment (Fig. 5) and
noticeable increase of the Granzym B+ CD8+ T tumor killing
cells (Fig. 4B), accompanied with reduced expression of Il10
and increased expression of Il12. Interestingly, the thera-
peutic effect of anti-IL-25 antibody closely resembles that of
anti-IL-4 blocking antibody as previously reported (DeNardo
et al., 2009), in that both treatments only reduced pulmonary
metastasis, but did not affect the primary tumor as well as
the survival of tumor-bearing mice in the MMTV-PyMT breast
tumor model. These results together highlight an essential
role of the IL-25/Th2 axis in controlling tumor progression
and tumor metastasis in breast cancer, suggesting that it
may serve as a novel target for treatment of metastatic
breast cancer.
IL-25 can be expressed by normal human breast epithe-
lial cells (Furuta et al., 2011), and its level was found to be
further elevated in human breast cancer biopsies in previous
studies (Mombelli et al., 2015). In our study, we found that IL-
25 was abundantly expressed in all four major types of
human breast cancer patients, and both tumor cells and
tumor-inﬁltrating cells expressed clearly high levels of IL-25.
These ﬁndings indicate a role of IL-25 in breast tumor
development. Indeed, two recent studies suggested an anti-
tumor activity based on in vitro culture system and xenograft
tumor model,through direct pro-apoptotic effect on tumor
cells (Furuta et al., 2011) or indirect mechanism (Benatar
et al., 2010), respectively. These reports are opposite to our
observations that anti-IL-25 treatment only reduced lung
metastasis, but did not affect the progression of primary
tumors. Unlike the previous in vitro studies, we noticed that
the tumor cells in the MMTV-PyMT tumor model did not
express IL-17RB – the receptor for IL-25 (Fig. 3B), and thus
could not respond directly to IL-25 treatment. Additionally, it
has been suggested that only a minority population of breast
cancer patients showed IL-17RB expression in the tumor







































































































Figure 4. Anti-IL-25 antibody treatment dampened Th2-responses in the primary tumor microenvironment. The MMTV-PyMT
mice were treated with either anti-IL-25 antibody or isotype control antibody starting from 4–5 weeks old, and sacriﬁced at 14 weeks
old for the following analysis. (A) Expression of IL-4, IL-5 and IL-13 in tumor inﬁltrating cells (gated on CD4+ cells), and the statistic
data were shown on the left. (B) Expression of PD-1 and Granzyme B in tumor inﬁltrating cells (gated on CD8+ cells), and the
statistical data were shown on the left.
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(18.8%) clinic sections from human breast tumors showed
IL-17RB expression (Furuta et al., 2011), whereas Huang
et al found that 38 out of 179 (21%, based on data presented
in Fig. 6B in the paper) showed membranous staining of IL-
17RB in the tumor cells (Huang et al., 2014). In line with the
clinic data, the expression of IL-17RB is also variable among
different breast tumor cell lines (Mombelli et al., 2015).
Moreover, Mombelli et al failed to reproduce the anti-tumor
activity of IL-25 on MCF-7, T47D or MDA-MB468 breast
tumor cell lines, even they express IL-17RB (Mombelli et al.,
2015). These contrasting data together highlights the
complexity and heterogeneous nature of breast tumors, and
thus IL-25 may play a distinct role in different tumor models.
Nevertheless, our ﬁndings are consistent with the well-
established role of IL-25 in boosting type 2 immune response
and thereby enhancing tumor metastasis in breast tumor
models.
IL-25 has been shown to be able to directly act on M2
macrophages and induce production of type 2 cytokines in
different disease models (Cao et al., 2011; Rizzo et al.,
2012). However, our studies showed that tumor macro-















































































































































Figure 5. Anti-IL-25 antibody treatment dampened the polarization of M2 macrophages in primary tumor. The MMTV-PyMT
mice were treated with either Rat IgG or anti-IL-25 antibody starting from 4 weeks old to 14 weeks old (3–7 mice/group), and then
sacriﬁced at 14 weeks old for the following analysis. (A) Staining of CD206 positive macrophage populations in mammary carcinomas
(shown as mean ± SE). (B) The relative mRNA level of YM-1 and Arg in sorted tumor macrophages or the relative mRNA level of Il10,
Il12, Tgfb and Tnfa genes in the total tumor tissue.
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17RB and thus cannot directly respond to IL-25, similar to
the alternatively activated macrophages as reported (Stolﬁ
et al., 2011). Further studies suggest that these macro-
phages can be categorized into two groups: tumor-resident
macrophages (CD206+YM-1+F4/80+Gr1-) and tumor-asso-
ciated macrophages (CD206-YM-1- F4/80+Gr1-), with the
former as the major tumor macrophage population that
respond to anti-IL-25 antibody treatment. The result differs
from the study using MMTV-PyMT mice on the C57/BL6
background, in which most tumor macrophages were char-
acterized as CD206- tumor associated macrophages and
were not affected by IL-4 deﬁciency (Franklin et al., 2014).
IL-25 can promote the expression of type 2 cytokines
including IL-4, IL-5 and IL-13 in different in vitro and in vivo
models. In this study, we noticed that anti-IL-25 treatment
only reduced the IL-4-producing Th2 cells in the tumor
microenvironment, but did not affect the expression of IL-5
and IL-13. Interestingly, a recent paper showed that IL-25
induced only IL-4 expression in Th2 cells at low dose (100
ng/ml), whereas induced IL-4, IL-5 and IL-13 expression at
high dose (1000ng/ml), suggesting that IL-25 regulates the
expression of different type 2 cytokine in a context-depen-
dent manner (Swaidani et al., 2011).
Despite anti-IL-25 treatment signiﬁcantly reduced lung
metastasis in the MMTV-PyMT tumor model, it did not affect
the growth of primary tumor and the survival of tumor mice.
In this model, the primary tumor grew enormously huge and
signiﬁcantly hindered the moving activity of tumor-bearing
mice when approaching death, whereas at the same time the
lung metastasis still remains at minimal sizes. Our ﬁndings
are consistent with several previous reports that inhibiting
metastasis alone in the MMTV-PyMT tumor model could not
improve the survival rate (Lin et al., 2001; DeNardo et al.,
2009; Zabuawala et al., 2010), suggesting that death in this
tumor model are mainly caused by uncontrolled growth of
primary tumors. Therefore, anti-IL-25 did not affect the sur-
vival of tumor-bearing mice in our hands.
In summary, our study, for the ﬁrst time, characterized
tumor-inﬁltrating tumor macrophages as the major source of
IL-25 in the MMTV-PyMT tumor mice, and demonstrated a
critical role of IL-25 in promoting tumor metastasis through
modulating type 2 immune response via targeting Th2 cells
in breast tumor model. In addition, we found that IL-25 was
broadly expressed in all the four major types of human
breast cancer patients. Considering that death in human
breast cancer patients are usually caused by tumor metas-
tasis, a combination of tumor surgery with anti-IL-25 treat-
ment may therefore provide a novel useful approach in
treatment of human breast cancer.
MATERIALS AND METHODS
Mice and tumor sections
The MMTV-PyMT transgenic mice (FVB background) were pur-
chased from Jackson laboratory. The mice were housed and bred
under SPF condition in the animal facility at Tsinghua University.
These experiments were approved by the Institutional Animal Care
and Use Committee of Tsinghua University.
A total of 40 breast tumor tissue sections were obtained from the
First Hospital of Jilin University, which include 10 of each major
breast cancer intrinsic subtypes (Luminal A, Luminal B, Triple neg-
ative/basal-like, and HER2-enriched) (Sorlie et al., 2001; Prat et al.,
2015). Written informed consent was obtained from all patients and
the experimental protocol was approved by the Institutional Review
Committee of Jilin University and the ethics committee of the First
Hospital of Jilin University.
Immunohistochemical and immunoﬂuorescence staining
For immunoﬂuorescence, frozen tissue sections were ﬁxed in cold
methanol for 10 minutes and air-dried. The sections were blocked for
30min with donkey serum and then incubated with a polyclonal goat
anti-mouse IL-25 antibody (Santa Cruz, sc-22148) overnight,
washed in PBS, and then incubated with TRITC-conjugated donkey
anti-goat immunoglobulin and with anti-mouse F4/80-AF488 or anti-
mouse CD4-AF488 for half an hour. The parafﬁn tissue sections
from human and mouse primary tumor or lung were incubated with
anti-IL-25 antibody (Millipore Cat. # 06-1080, which can bind both
human and mouse IL-25) followed by visualization using rabbit
Speciﬁc HRP/DAB Detection IHC Kit (ZSGB-BIO, PV-6001, ZLI-
9017) (IHC: Immunohistochemistry) according to the manufacturer’s
instructions. Staining was visualized by Zeiss microscope and
analyzed by Image-Pro plus software.
Anti-IL-25 administration and estimation of tumor growth
and metastases
MMTV-PyMT mice were treated intraperitoneally with the anti-IL-25
antibody or control antibody (Rat IgG) around the onset time of
primary tumors (∼4–5 weeks’ old). The treatment continued for
about ten weeks (200 μg per injection in 200 μl PBS, twice per
week). The size of primary mammary tumors was measured using
electronic calipers and calculated as (length × width × height)/2,
pulmonary tissue sections were stained with H&E for analysis of
metastatic tumors by light microscope and Image-Pro Plus. In this
study, the IL-25 blocking antibody (clone# 35B) was initially gen-
erated and characterized by our lab through screening a panel of
rat anti-mouse IL-25 IgG for the ability to inhibit the binding of IL-25
to 293 cells transfected with IL-17RB (Angkasekwinai et al., 2007).
This antibody is now commercially available at BioLegend
(Cat#514404)
Real-time RT-PCR
Total RNA was extracted from mouse breast tissue or sorted cells by
Trizol reagent (Invitrogen) according to manufacturer’s instructions.
Two micrograms of total RNA was reversely transcripted into cDNA
by using cDNA Reverse Transcription Kit (Invitrogen). Real-time
qRT-PCR was performed in CFX96 Touch™ Real-Time PCR
Detection System (BioRad) using iTaq™ Universal SYBR® Green
Supermix (BioRad) and speciﬁc primers for Il25, Il17rb, Arg, Cd206,
Ym1, Il10,Il12, Tgfb and Tnfa, and normalized to the housekeeping
gene GAPDH (Supplementary data 4).
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Preparation of tumor-inﬁltrating cells
Tumor tissues from MMTV-PyMT mice were minced and digested in
DMEM medium containing 1 mg/mL collagenase A, 2.0 units/ml
DNase (all from Roche) for 2 h at 37°C with periodic vortex. Tumor
inﬁltrating cells were puriﬁed by Percoll density gradient centrifuga-
tion, stained with different surface markers as indicated in the paper,
and then analyzed by ﬂow cytometry.
FACS analysis and cell sorting
Fluorochrome labeled anti-mouse mAbs speciﬁc for CD45(30-F11),
CD45R (RA3-6B2),CD3 (17A2), CD11b (M1/70), CD4 (GK1.5), CD8
(53-6.7), CD49b(DX5), γδTCR(GL-3),MHC class II (M5/114.15.2),
F4/80 (BM8), CD25 (PC61), Ly6G (1A8), Ly6C (AL-21), Ly- 6C/G
(RB6/8C5), Siglec-F (E50-2440), ST2 (DIH9), and IL-17RB antibody
(752101) were used for ﬂow cytometry analyses. For intracellular
staining, puriﬁed cells were stimulated with PMA (50 ng/ mL)/iono-
mycin (500 ng/mL) (Sigma-Aldrich) with GolgiStop (BD Pharmingen,
NJ) for 4 hrs and stained with ﬂuorochrome-labeled anti-mouse
mAbs speciﬁc for CD206 (C068C2),GzmB (NGZB) Foxp3 (MF23),
IL-4 (BVD4- 1D11), IL-5 (TRFK5), IL-13 (eBio13A) (BD Pharmingen/
BioLegend, San Diego, CA/eBiosciences, San Diego, CA). Cells
were analyzed with BD LSRFortessa™ cell analyzer (BD Bio-
sciences, San Jose, CA) and the analysis was conducted with
FlowJo software. Macrophages, CD4+ T cells and CD45 negative
tumor cells were sorted using a FACSAria (BD) according to their
corresponding surface markers.
Statistical analysis
The statistic signiﬁcance of our data was analyzed by Student’s t test
using Prism (version 5.00; GraphPad Software). (*P < 0.05;
**P < 0.01; ***P < 0.001). All the experiments in the paper was
repeated 2–4 times with consistent results.
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